Hepatitis is usually caused by a viral infection but can also result from liver damage caused by drinking alcohol. People infected with the hepatitis A or B virus usually recover in a couple of months. But over 200,000 people in the UK are affected by Hepatitis C. After years or even decades, infection can lead to liver damage that is potentially life-threatening. On this page are a number of articles related to hepatitis, including coverage of the advent of new and highly effective drugs for Hepatitis C, how they work and also the struggle for the health system to afford them.
Hepatitis C: tackling the silent killerSubscription
About 200,000 people are living with hepatitis C in the UK, but it is estimated that around half of these remain undiagnosed. Identifying those at risk, offering tests and connecting those infected with treatment are crucial to tackling the disease.
Community pharmacists could be involved in detecting undiagnosed cardiovascular disease under plans laid out in the ‘The Community Pharmacy Contract Framework for 2019/20 to 2023/24’.
Deaths from liver disease related to serious hepatitis C fell by more than 16% between 2015 and 2017, according to data published by Public Health England.
Incidence of hepatitis C has fallen by almost 70% in HIV positive men who have sex with men living in London since 2015, according to research presented at a major HIV conference.
Study shows needle and syringe programmes reduce transmission of hepatitis C while delivering cost savings.
Results of a four-month pilot project show that more than half of patients using pharmacy-based needle exchange services tested positive for hepatitis C antibodies.
A “radical change” in the health service’s response to the hepatitis C virus among people who inject drugs is required if NHS England’s target to eliminate the disease by 2025 is to be met.
NHS England has no hope of meeting its target to eliminate hepatitis C by 2025 unless the government develops a national strategy to wipe out the curable and preventable virus.
We read with interest the article by Cook and Buchanan in the November issue of The Pharmaceutical Journal.